Our purpose is to accelerate the development of cancer medicines and treatments
Talk to our team
We’d like to hear from you
Read the latest news from Ellipses Pharma
Ellipses Pharma featured in Nature Research
Ellipses Pharma featured in Nature Research Ellipses Pharma: maximizing KOL input to increase the success rate of oncology R&D. Read the full article here.
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that [...]
Expansion of Scientific Affairs Group
Expansion of Scientific Affairs Group More than 200 oncologists worldwide now involved in assessment and selection of potential treatments Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG). Ellipses [...]
